8-K Announcements
6Material company update
Mar 18, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Jan 30, 2026·SEC
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028(ABLLL)Earnings, Financials & Key Ratios
ABLLL•NASDAQ•Insurance & Managed Care
$25.61
$2.5B mkt cap·Price updated Apr 24, 2026
AboutAbacus Life, Inc. is an integrated alternative asset manager, which engages in the business of investing in inforce life insurance products. The firm is involved in purchasing outstanding life insurance policies to connect buyers and sellers through an origination process. The company was founded by Matthew Ganovsky, Kevin Scott Kirby, and Todd Sean McNealy and is headquartered in Orlando, FL.Show more
- Revenue$112M+68.6%
- Combined Ratio100.79%+58.3%
- Net Income-$24M-351.8%
- Return on Equity-8.16%-182.4%
- Medical Cost Ratio10.16%+3.9%
- Operating Margin-0.79%-102.2%
- Net Margin-21.41%-249.4%
- ROA-3.97%-181.6%
- Equity / Assets48.42%-2.1%
- Book Value per Share5.98+110.6%
- Tangible BV/Share1.49+1570.7%
- Debt/Equity0.91+5.5%
ABLLL Key Insights
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 73.6%
- ✓Low loss ratio of 10.2%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 22.5% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABLLL Price & Volume
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) stock price & volume — 10-year historical chart
Loading chart...
ABLLL Growth Metrics
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years70.47%
TTM91.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM192.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM152%
Return on Capital
10 Years63.83%
5 Years63.83%
3 Years42.61%
Last Year-0.16%
ABLLL Recent Earnings
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (14%)●Beat Revenue 6/12 qtrs (86%)
Q2 2026Latest
Mar 13, 2026EPS
$0.07
Revenue
$72M
Q4 2025
Nov 5, 2025EPS
$0.07
Est $0.18
-60.4%
Revenue
$63M
Est $50M
+25.5%
Q3 2025
Aug 11, 2025EPS
$0.18
Est $0.16
+10.5%
Revenue
$56M
Est $43M
+30.6%
Q2 2025
May 12, 2025EPS
$0.07
Est $0.16
-58.5%
Revenue
$44M
Est $40M
+9.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 13, 2026 | $0.07 | $72M |
| Q4 2025 | Nov 5, 2025 | $0.07vs $0.18-60.4% | $63Mvs $50M+25.5% |
| Q3 2025 | Aug 11, 2025 | $0.18vs $0.16+10.5% | $56Mvs $43M+30.6% |
| Q2 2025 | May 12, 2025 | $0.07vs $0.16-58.5% | $44Mvs $40M+9.3% |
Based on last 12 quarters of dataView full earnings history →
ABLLL Peer Comparison
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) competitors in Legacy blocks and life policy investors — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABL | 790.82M | 8.09 | -23.79 | -100% | 11.27% | |||
 HIFS | 632.2M | 289.70 | 22.54 | 14.09% | 9.79% | 3.47 | ||
 CSWC | 1.44B | 24.19 | 16.46 | 7.67% | 10.32% | 1.08 | ||
 PFLT | 913.8M | 9.21 | 12.79 | 2.2% | 3.23% | 1.65 | ||
 LPLA | 26.05B | 324.88 | 29.75 | 37.18% | 18.57% | 1.36 | ||
 ERIE | 9.86B | 213.56 | 20.11 | 7.17% | 13.2% | 25.03% | ||
 FGL | 33.84M | 2.00 | -118.74 | -38.98% | -32.28% | 2.09 | ||
 RLI | 4.51B | 49.01 | 11.24 | 6.33% | 20.8% | 22% | 0.06 |
Compare ABLLL vs Peers
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABLLL Income Statement
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.22M | 22.59M | 44.71M | 66.4M | 111.92M | 196.55M |
| Revenue Growth % | - | 1744.73% | 97.92% | 48.5% | 68.56% | 91.93% |
| Medical Costs & Claims | 514.67K | 14.21M | 5.88M | 6.49M | 11.37M | 24.54M |
| Medical Cost Ratio % | 42.02% | 62.88% | 13.16% | 9.77% | 10.16% | 12.48% |
| Gross Profit | 710.01K▲ 0% | 8.39M▲ 1081.2% | 38.83M▲ 363.0% | 59.91M▲ 54.3% | 100.55M▲ 67.8% | 172.01M▲ 0% |
| Gross Margin % | 57.98% | 37.12% | 86.84% | 90.23% | 89.84% | 87.52% |
| Gross Profit Growth % | - | 1081.22% | 362.98% | 54.3% | 67.84% | - |
| Operating Expenses | -641.33K | 7.45M | 5.16M | 35.79M | 101.44M | 122.82M |
| OpEx / Revenue % | -52.37% | 32.97% | 11.55% | 53.89% | 90.63% | 62.49% |
| Depreciation & Amortization | 0 | 31.24K | 4.28K | 3.41M | 7.91M | 17.08M |
| Combined Ratio % | -10.34% | 95.85% | 24.71% | 63.67% | 100.79% | 74.97% |
| Operating Income | 1.35M▲ 0% | 937.12K▼ 30.7% | 33.67M▲ 3492.4% | 24.13M▼ 28.3% | -888.3K▼ 103.7% | 49.2M▲ 0% |
| Operating Margin % | 110.34% | 4.15% | 75.29% | 36.33% | -0.79% | 25.03% |
| Operating Income Growth % | - | -30.65% | 3492.44% | -28.34% | -103.68% | - |
| EBITDA | 662.02K | 968.36K | 33.67M | 27.54M | 7.02M | 66.27M |
| EBITDA Margin % | 54.06% | 4.29% | 75.3% | 41.47% | 6.27% | 33.72% |
| Interest Expense | 0 | 0 | 42.8K | 9.87M | 18.28M | 33.97M |
| Non-Operating Income | 689.33K | -61.5K | 345.54K | 3.76M | 265.31K | -9.75M |
| Pretax Income | 662.02K▲ 0% | 998.62K▲ 50.8% | 33.28M▲ 3232.3% | 10.5M▼ 68.4% | -19.43M▼ 285.0% | 24.98M▲ 0% |
| Pretax Margin % | 54.06% | 4.42% | 74.42% | 15.82% | -17.36% | 12.71% |
| Income Tax | 1.56K | 1.2K | 889.94K | 1.47M | 5.48M | 13.9M |
| Effective Tax Rate % | 0.24% | 0.12% | 2.67% | 13.98% | -28.22% | 55.65% |
| Net Income | 662.02K▲ 0% | 997.41K▲ 50.7% | 31.68M▲ 3076.4% | 9.52M▼ 70.0% | -23.96M▼ 351.8% | 11.04M▲ 0% |
| Net Margin % | 54.06% | 4.41% | 70.86% | 14.33% | -21.41% | 5.62% |
| Net Income Growth % | - | 50.66% | 3076.44% | -69.96% | -351.78% | 192.58% |
| EPS (Diluted) | -0.25▲ 0% | 0.37▲ 248.0% | -0.02▼ 105.9% | 0.16▲ 833.9% | -0.34▼ 312.5% | 0.11▲ 0% |
| EPS Growth % | - | 248% | -105.89% | 833.94% | -312.5% | 152% |
| EPS (Basic) | -0.25 | 0.37 | -0.02 | 0.17 | -0.34 | - |
| Diluted Shares Outstanding | 43.13M | 43.13M | 29.55M | 57.77M | 70.76M | 96.65M |
ABLLL Balance Sheet
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Assets | 1.46M | 1.84M | 59.09M | 331.83M | 874.16M | 918.94M |
| Asset Growth % | - | 25.94% | 3111.3% | 461.51% | 163.44% | 454.21% |
| Total Investment Assets | 1.25M | 1.5M | 3.19M | 129.1M | 375.54M | 4M |
| Long-Term Investments | 1.25M | 1.5M | 3.19M | 126.85M | 375.54M | 1.25B |
| Short-Term Investments | 0 | 0 | 0 | 2.25M | 0 | 0 |
| Total Current Assets | 211.2K | 194.82K | 33.28M | 31.78M | 159.56M | 138.15M |
| Cash & Equivalents | 135.27K | 102.42K | 30.05M | 25.59M | 131.94M | 86.42M |
| Receivables | 0 | 0 | 208.81K | 3.24M | 26.53M | 98.63M |
| Other Current Assets | 74.76K | 67.49K | 2.9M | 699.13K | 1.09M | 21.34M |
| Goodwill & Intangibles | 0 | 0 | 0 | 169.91M | 318.08M | 1.26B |
| Goodwill | 0 | 0 | 0 | 140.29M | 238.3M | 248.96M |
| Intangible Assets | 0 | 0 | 0 | 29.62M | 79.79M | 70.49M |
| PP&E (Net) | 0 | 145.4K | 95.63K | 2.29M | 5.75M | 6.31M |
| Other Assets | 0 | 0 | 22.53M | 998.95K | 15.23M | 445.18M |
| Total Liabilities | 160.7K | 1.07M | 30.95M | 167.76M | 450.87M | 479.34M |
| Total Debt | 148.97K | 1.05M | 28.59M | 141.74M | 385.91M | 124.71M |
| Net Debt | 13.7K | 950.71K | -1.46M | 116.15M | 253.97M | 38.29M |
| Long-Term Debt | 0 | 0 | 28.25M | 126.79M | 342.39M | 4.54M |
| Short-Term Debt | 148.97K | 930.63K | 263.79K | 13.03M | 38.43M | 120.17M |
| Total Current Liabilities | 160.7K | 995.93K | 1.3M | 23.33M | 62.47M | 148.44M |
| Accounts Payable | 0 | 0 | 40.01K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 507K | 2.47M | 0 |
| Other Current Liabilities | 11.73K | 20.19K | 950.48K | 3.4M | 14.42M | 28.27M |
| Deferred Taxes | 0 | 0 | 0 | 1000K | 1000K | 114.61M |
| Other Liabilities | 0 | 0 | 1.36M | 6.64M | 14.66M | 295.13M |
| Total Equity | 1.3M▲ 0% | 766.89K▼ 41.0% | 28.15M▲ 3570.6% | 164.07M▲ 482.8% | 423.29M▲ 158.0% | 439.59M▲ 0% |
| Equity Growth % | - | -41.03% | 3570.62% | 482.85% | 158% | 455.98% |
| Shareholders Equity | 1.3M | 915.05K | 27.25M | 163.93M | 424.15M | 439.59M |
| Minority Interest | 0 | -148.16K | 899.54K | 138.28K | -857.83K | 0 |
| Retained Earnings | 590.5K | 205.05K | 25.49M | -34.73M | -57.9M | 0 |
| Common Stock | 50K | 50K | 5.04K | 6.34K | 10.13K | 0 |
| Accumulated OCI | 0 | 0 | 1.05M | 108.37K | 0 | 0 |
| Return on Equity (ROE) | 50.91% | 96.49% | 219.13% | 9.9% | -8.16% | 2.51% |
| Return on Assets (ROA) | 45.31% | 60.42% | 103.99% | 4.87% | -3.97% | 1.2% |
| Equity / Assets | 89% | 41.67% | 47.63% | 49.44% | 48.42% | 47.84% |
| Debt / Equity | 0.11x | 1.37x | 1.02x | 0.86x | 0.91x | 0.91x |
| Book Value per Share | 0.03 | 0.02 | 0.95 | 2.84 | 5.98 | 4.55 |
| Tangible BV per Share | 0.03 | 0.02 | 0.95 | -0.10 | 1.49 | 1.24 |
ABLLL Cash Flow Statement
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | 650.13K | 1.34M | -2.6M | -64.52M | -208.81M | -208.81M |
| Operating CF Growth % | - | 106.54% | -293.8% | -2379.48% | -223.62% | -2887.52% |
| Operating CF / Revenue % | 53.09% | 5.94% | -5.82% | -97.17% | -186.56% | -106.24% |
| Net Income | 662.02K | 997.41K | -643.56K | 9.03M | -23.96M | 11.04M |
| Depreciation & Amortization | 0 | 31.24K | 4.28K | 3.41M | 7.91M | 17.08M |
| Stock-Based Compensation | 0 | 0 | 0 | 10.77M | 43.44M | 35.13M |
| Deferred Taxes | 0 | 0 | 889.94K | 466.58K | 6M | 6.63M |
| Other Non-Cash Items | 0 | 0 | 15.13M | -18.47M | -46.47M | -54.38M |
| Working Capital Changes | -11.88K | 314.1K | -17.98M | -69.73M | -195.73M | -125.75M |
| Cash from Investing | -1.25M | -241.53K | 246.5M | 2.24M | -4.96M | -17.77M |
| Capital Expenditures | 0 | -226.66K | -79.1K | -189.67K | -805.14K | -1.01M |
| Acquisitions | 16.4K | -14.86K | 0 | 0 | -2.43M | -564.15K |
| Purchase of Investments | -1.25M | -250K | -1.92M | -350K | -1.2M | -5.5M |
| Sale/Maturity of Investments | 0 | 0 | 1000K | 0 | 0 | 0 |
| Other Investing | -16.4K | 250K | 79.1K | 2.78M | -519.53K | -9.6M |
| Cash from Financing | 697.81K | -354.58K | -244.66M | 57.82M | 320.12M | 195M |
| Dividends Paid | -327.8K | -358.22K | -659.36K | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -6.4M | -24.82M | -10.74M | -38.71M |
| Stock Issued | 0 | 0 | 0 | 972.26K | 181.7M | 89.7M |
| Debt Issuance (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1.24M |
| Other Financing | 1.03M | 3.64K | -25.94M | -38.84M | -17.08M | -16.02M |
| Net Change in Cash | 97.95K▲ 0% | 746.66K▲ 662.3% | -766.56K▼ 202.7% | 25.5M▲ 3426.8% | 106.36M▲ 317.0% | 67.01M▲ 0% |
| Exchange Rate Effect | 0 | 0 | 0 | 1000K | 0 | 0 |
| Cash at Beginning | 37.33K | 1.85M | 853.13K | 86.57K | 25.59M | 74.84M |
| Cash at End | 135.27K | 2.6M | 86.57K | 25.59M | 131.94M | 86.42M |
| Free Cash Flow | 650.13K▲ 0% | 1.12M▲ 71.7% | -2.68M▼ 340.2% | -64.71M▼ 2313.4% | -209.62M▼ 223.9% | -111.15M▲ 0% |
| FCF Growth % | - | 71.67% | -340.25% | -2313.41% | -223.92% | 14.97% |
| FCF Margin % | 53.09% | 4.94% | -6% | -97.46% | -187.28% | -56.55% |
| FCF per Share | 0.02 | 0.03 | -0.09 | -1.12 | -2.96 | -2.96 |
ABLLL Key Ratios
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Combined Ratio | 95.85% | 24.71% | 63.67% | 100.79% | 74.97% |
| Medical Cost Ratio | 62.88% | 13.16% | 9.77% | 10.16% | 12.48% |
| Return on Equity (ROE) | 96.49% | 219.13% | 9.9% | -8.16% | 2.51% |
| Return on Assets (ROA) | 60.42% | 103.99% | 4.87% | -3.97% | 1.2% |
| Equity / Assets | 41.67% | 47.63% | 49.44% | 48.42% | 47.84% |
| Book Value / Share | 0.02 | 0.95 | 2.84 | 5.98 | 4.55 |
| Debt / Equity | 1.37x | 1.02x | 0.86x | 0.91x | 0.91x |
| Revenue Growth | 1744.73% | 97.92% | 48.5% | 68.56% | 91.93% |
ABLLL SEC Filings & Documents
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABLLL Frequently Asked Questions
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) grew revenue by 68.6% over the past year. This is strong growth.
Yes, Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) is profitable, generating $11.0M in net income for fiscal year 2024 (-21.4% net margin).
Dividend & Returns
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) has a combined ratio of 100.8%. A ratio above 100% means claims and expenses exceed premiums.
Explore More ABLLL
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates